“Small and emerging biopharma companies continue to be responsible for more of the molecules making their way to market, as demonstrated by record FDA approvals in 2023. We remain positive for 2024 as we begin to see early signs of a return to increasing biotech industry funding to support the growing number of new molecules in the development pipelines.”

Thierry Van Nieuwenhove, CEO, Quotient Sciences

“The development of ADCs as a therapeutic category faced challenges initially, dating back to the 2000s. However, with advancements in targeting and aligning on a molecular level, it has evolved into a prominent modality across therapeutic categories. We anticipate this trend to persist, contingent on ongoing clinical proof points. The entire value chain, encompassing ADC linker warheads, conjugation, and fill-finish, is poised for growth.”

Nick Shackley, SVP and Chief Commercial Officer, Veranova

“The biologics market continues its upward trajectory, representing a significant and ever-expanding segment of the pharmaceutical industry. However, amidst this growth, challenges such as drug shortages underscore the widening gap between manufacturing capacities and market demands. Nonetheless, innovation thrives, with new biologics approvals and Phase 3 trials underway, signaling a promising outlook for the industry.”

Jueon Kang, Chief Planning and Information Security Officer, Lotte Biologics

“The demand for large molecule manufacturing, whether mammalian or microbial, continues to increase and grow faster than small molecule manufacturing. This is an unsurprising trend as large molecules are disease-alternating, not just symptom-treating.”

Axel Schleyer, CCO, Cytovance Biologics

“Biologics will continue to be a strong growth area. As such, there is also a growing focus on patient-centric dosage forms such as long-acting injectables, implants, and drug delivery devices aimed at enhancing patient comfort and safety.”

Robert W. Lee, Senior Vice President, Particle Sciences, Inc., an Agno Pharma Company